**Background:** The Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) is a novel zoonotic virus emerged in 2012 in the Middle East. Accumulating body of evidence suggests that dromedaries are the main known reservoir hosts. Nonetheless, both Human-to-human and camel-to-human transmissions have been reported. So far, only 2,090 confirmed cases have been reported in 27 countries with a high mortality rate of 30--40%. However, prevalence of MERS-CoV in the general population is still not clear and epidemiological studies are limited especially in Saudi Arabia which is the most affected country. Therefore, our main goal in this study was to determine the sero-prevalence of MERS-CoV among healthy people in the western region of Saudi Arabia.

**Methodology:** A total of 7, 462 archived serum samples collected between 2011 and 2016 from healthy blood donors in the western region of Saudi Arabia were screened by ELISA tests for the presence of MERS-CoV antibodies. All ELISA positive samples were tested for presence of neutralizing antibodies using MERS-CoV neutralization assay.

**Results:** The indirect ELISA results showed that the seroprevalence of MERS-CoV for the years 2011, 2012 and 2013 were 1.11% (1/90), 0.74% (10/1360) and 1.8% (18/999), respectively. Interestingly, testing samples from 2016 showed increased seroprevalence of 3.01% (151/5013).

The cumulative overall seroprevalence of MERS-CoV for all years was 2.41% (180/7,462). Interestingly, none of the positive samples showed any evidence of neutralizing antibodies.

**Conclusion:** Our data here showed that MERS-CoV or a closely related coronavirus might have been circulating before 2012 in Saudi Arabia. Data also suggest that there might be several cases that are undiagnosed or missed probably due to mild or asymptomatic infections which could resulted in the observed very low or undetectably neutralizing antibodies. Interestingly, we found that seroprevalence of MERS-CoV is increasing over the years underscoring the importance for continued active surveillance for MERS-CoV.
